Evidence from knockdown experiments supports the therapeutic potential of RPS6 targeting in various cancer cells including breast cancer, cervical carcinoma, head and neck cancer, gastric cancer, glioblastoma, HCC, hematopoietic cancer, lung cancer, melanoma, ovarian cancer, and sarcoma (Figure 5). Here, RPS6 is linked to hematopoietic and lymphoid cell neoplasm.